VivoSim Labs partners with Chemveda to test AI-designed drug candidates in human tissue models
VIVS•VivoSim Labs and Chemveda Life Sciences will screen AI-designed drug candidates using human liver and intestine models, with initial programs expected in Q4 2026. The screening can evaluate more than 20 compounds in two weeks.
1. Joint screening offering
VivoSim Labs entered a strategic collaboration with Chemveda Life Sciences to screen AI-designed drug candidates using human tissue models. Testing will use human liver and intestine models, and initial programs are expected in Q4 2026.
2. Screening details
The joint offering will serve Chemveda’s global clients. Screening can evaluate more than 20 compounds in two weeks and provide early toxicity and efficacy feedback to guide molecular design.
